Evaluation of Novel Diagnostic Tests for COVID-19

Coronavirus Clinical Trial

— COVIDx  

Official title:

Evaluation of Novel Diagnostic Tests for 2019-nCOV

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04326387
• Other study ID #: COVIDx
• Status: Recruiting
• Start date: April 6, 2020
• Est. completion date: October 7, 2021

Study information

• Verified date: May 2020
• Source: Cambridge University Hospitals NHS Foundation Trust
• Contact: Richard D. Skells, BSc.
• Phone: 01223 349707
• Email: richard.skells[@]addenbrookes.nhs.uk
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

COVID-19 (also known as Coronavirus) originated in the Wuhan China and has since spread to at least 159 countries around the world. It was declared a pandemic by the World health organisation on the 11th of March 2020. The cases in the United Kingdom continue to increase exponentially with up to 5 683 people diagnosed as on the 22nd of March 2020. It is estimated that 1 in 5 people diagnosed will require hospital admission and 1 in 20 intensive care treatment. By developing and improving diagnostic testing, we can accurately diagnose infected cases to triage appropriate treatments, identify individuals for quarantine in order to prevent transmission and obtain information regarding patient's immune systems.

At present, the diagnostic test is a highly specific method of genetic amplification called 'Reverse Transcription - Polymerase Chain Reaction' or RT-PCR, which allows detection of very small amounts of genetic mutations caused by the COVID-19 virus. However, this method must be completed in highly specialised facilities, which are few and far between, increasing time to diagnosis (currently 48-72 hours), increasing exposure to non-infected individuals, and overburdening the analysing facilities. The ideal solution is a point of care (POC) test that can give results immediately. This study aims to harness the point of care technology of the SAMBA II device (Diagnostics for the Real World Ltd.), which is a CE-marked device that has been used with success in the identification of Human Immunodeficiency Virus (HIV), by amplifying genetic material without the need to increase and decrease temperatures during the amplification process.

In the COVIDx study, 200 patients meeting the Public Health England's (PHE) inpatient definition of having suspected COVID-19 will be approached, consented and a sample from throat and nasal swab (combined) or tracheal fluid taken and tested using the SAMBA II method. A combination of the standard PHE RT-PCR and an additional validated laboratory PCR technique will be used as a control in line with standard clinical practice. Patients will undergo an additional serum tests on existing samples as made available after routine clinical assessments to monitor antibody response. Patients will be followed for clinical outcomes at 28 days post-admission.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: October 7, 2021
• Est. primary completion date: April 7, 2021
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

• 16 years or above

• Patient requiring hospital admission AND AT LEAST ONE OF

• Clinical or Radiological evidence of pneumonia

• Acute respiratory distress syndrome

• Influenza like illness (defined as fever >37.8oC and at least one of the following respiratory symptoms, which much be of acute onset: persistent cough (with or without sputum), hoarseness, nasal discharge or congestion, shortness of breath, sore throat, wheezing, sneezing)

Exclusion Criteria:

• Patients who have not had the standard PHE COVID-19 test applied

• Unwilling or unable to comply with research swab of nose & throat or tracheal fluid

Related Conditions & MeSH terms

• Acute Disease
• Coronavirus
• Coronavirus Infections
• Respiratory Viral Infection
• Virus Diseases

Intervention

Diagnostic Test:
• SAMBA II (Diagnostic for the Real World)
Point of care Isothermal-PCR Viral RNA Amplication for virus detection
• Public Health England Gold Standard
Reverse Transcription PCR
• Cambridge Validated Viral Detection Method
Reverse Transcription PCR
• Radiological Detection
Chest X-ray & CT Scan detection of viral infection in the lungs

Locations

Country	Name	City	State
United Kingdom	Cambridge University Hospitals NHS Foundation Trust	Cambridge	Cambridgeshire

Sponsors (1)

Lead Sponsor	Collaborator
CCTU- Cancer Theme

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	SAMBA COVID-19 POC PCR Test	Measuring the diagnostic accuracy of the SAMBA II POC-sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) tested against a dual composite reference standard	28 days
Secondary	Patient acceptability	Evaluating the participant acceptability of the SAMBA swab intervention using a participant reported discomfort scale	28 days
Secondary	Immune Response Positivity	Time to positive IgM/IgG test positivity	40 days